Evidence map›Paper›PMID 38672094›Full record

ReviewBiomedicines2024

Swollen Feet: Considering the Paradoxical Roles of Interleukins in Nephrotic Syndrome.

Maria E Kovalik, Monique A Dacanay, Steven D Crowley, Gentzon Hall

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Maria E KovalikDivision of Nephrology, Duke University, Durham, NC 27701, USA.ORCID 0000-0003-2913-1533
Monique A DacanayDivision of Nephrology, Duke University, Durham, NC 27701, USA.
Steven D CrowleyDivision of Nephrology, Duke University, Durham, NC 27701, USA.
Gentzon HallDivision of Nephrology, Duke University, Durham, NC 27701, USA.
Duke University · US

Funding

Resource Core 3 - Metabolomics CoreP30AG028716 · NIA · DUKE UNIVERSITY · PI CATHLEEN S COLON-EMERIC, Susan Nicole Hastings · 2006 to 2026
$24.6M
The Role of Interleukin-15 Receptor-alpha Variants in the Pathogenesis of FSGSK08DK111940 · NIDDK · DUKE UNIVERSITY · PI HALL, GENTZON · 2017 to 2021
$794k
The role of the M1 macrophage response in the progression of chronic kidney diseaseI01BX000893 · VA · DURHAM VA MEDICAL CENTER · PI Steven D Crowley · 2012 to 2026
–
BLRD VA I01 BX000893NIA NIH HHS P30 AG028716NIDDK NIH HHS K08 DK111940NIH/NIDDK DK08DK111940
6 · The paper itself

Abstract

Interleukins are a family of 40 bioactive peptides that act through cell surface receptors to induce a variety of intracellular responses. While interleukins are most commonly associated with destructive, pro-inflammatory signaling in cells, some also play a role in promoting cellular resilience and survival. This review will highlight recent evidence of the cytoprotective actions of the interleukin 1 receptor (IL-1R)- and common gamma chain receptor (IL-Rγc)-signaling cytokines in nephrotic syndrome (NS). NS results from the injury or loss of glomerular visceral epithelial cells (i.e., podocytes). Although the causes of podocyte dysfunction vary, it is clear that pro-inflammatory cytokines play a significant role in regulating the propagation, duration and severity of disease. Pro-inflammatory cytokines signaling through IL-1R and IL-Rγc have been shown to exert anti-apoptotic effects in podocytes through the phosphoinositol-3-kinase (PI-3K)/AKT pathway, highlighting the potential utility of IL-1R- and IL-Rγc-signaling interleukins for the treatment of podocytopathy in NS. The paradoxical role of interleukins as drivers and mitigators of podocyte injury is complex and ill-defined. Emerging evidence of the cytoprotective role of some interleukins in NS highlights the urgent need for a nuanced understanding of their pro-survival benefits and reveals their potential as podocyte-sparing therapeutics for NS.

Indexed as

cytoprotectionimmunotherapeuticsinterleukinsnephrotic syndromepodocytes

Identifiers

PMID38672094
PMCPMC11048099
OpenAlexW4393187029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.